Related Experiment Video
Updated: Aug 14, 2026

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)
Published on: April 21, 2019
IGN-311. Igeneon
1Institute of Cancer Research, The Breakthrough Toby Robins Breast Cancer Research Center, 237 Fulham Road, London SW3 6JB, UK. Hartmut.Kristeleit@icr.ac.uk
Igeneon, under license from Protein Design Labs, is developing IGN-311, an intravenous humanized monoclonal antibody against the Lewis Y carbohydrate antigen, as a potential agent for the passive immunotherapy of cancer, particularly epithelial tumors affecting breast, colon, gastric and pancreatic tissues. A phase I/II trial of IGN-311 was initiated in July 2005.
Igeneon, under license from Protein Design Labs, is developing IGN-311, an intravenous humanized monoclonal antibody against the Lewis Y carbohydrate antigen, as a potential agent for the passive immunotherapy of cancer, particularly epithelial tumors affecting breast, colon, gastric and pancreatic tissues. A phase I/II trial of IGN-311 was initiated in July 2005.
More Related Videos
Related Concept Videos
iChip
In-vitro Mutagenesis
IP3/DAG Signaling Pathway
Precipitation Reactions
Acids, Bases and Neutralization Reactions
Induction
A...

